Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
May 08, 2026
iShares U.S. Medical Devices ETF (IHI): Analyzing the -8.5% Drop Over the Past 30 Days

iShares U.S. Medical Devices ETF (IHI): Analyzing the -8.5% Drop Over the Past 30 Days

Key Takeaways

  • IHI declined approximately -8.5% over the past 30 days amid softer demand for medical devices and broader healthcare sector pressures.
  • Over the past quarter, the ETF fell around -15%, underperforming the broader health category due to valuation adjustments and muted procedural volumes.
  • Top holdings like ISRG and EW contributed significantly to the downside, while gains in ABT and SYK provided limited offset.
  • Higher interest rates and sector rotation away from growth-oriented healthcare stocks weighed on performance.
  • Fund flows showed net outflows over the past year, reflecting reduced investor interest in the niche medical devices theme.

Understanding IHI and Its Portfolio Focus

The iShares U.S. Medical Devices ETF (IHI) tracks the Dow Jones U.S. Select Medical Equipment Index, offering targeted exposure to U.S. companies that manufacture and distribute medical devices, including imaging equipment, prosthetics, and surgical tools. It holds about 52 stocks, with the top 10 making up over 75% of assets. Key positions include ISRG (Intuitive Surgical, ~16.5%), ABT (Abbott Laboratories, ~16%), and SYK (Stryker, ~11%). The portfolio is entirely allocated to healthcare, zeroing in on the medical devices subsector. This focus makes IHI particularly sensitive to industry challenges like reduced hospital spending and procedural delays, which has amplified its recent declines relative to more diversified healthcare ETFs.

IHI's Recent Price Action: 30 Days and Quarterly View

In the last 30 days, IHI fell from around $54.35 to $49.77, marking a -8.5% decline. The path was volatile and downward-trending, with sharp drops in late April speeding up the selloff. Over the past quarter, the retreat was even steeper at -15% from near $58.50 levels, driven by steady erosion amid broader market shifts. These moves line up with trailing returns of -4.3% for the prior month and -14.9% for three months as of early May, pointing to a bearish, range-bound pattern with lower highs. From what I see, this confirms ongoing pressure in the space.

Key Drivers Behind IHI's 30-Day Decline

The ETF's downturn over the past 30 days came mainly from weakness in its largest holdings and sector headwinds. Top holding ISRG dropped over 2%, pulling IHI lower given its 16.5% weight, while EW (Edwards Lifesciences) slid on concerns about cardiac device demand. Gains in ABT (up significantly) and SYK offered some cushion, but the portfolio's concentration magnified the losses. Softer demand for implants and neurotechnology—evident in Stryker's Q1 earnings miss—added to the strain. On the macro side, high interest rates raised financing costs for growth-reliant medtech companies, spurring profit-taking. Net fund outflows and a shift in sentiment toward value sectors only intensified the pressure. I also checked this using Tickeron’s AI Screener to gauge how IHI stacks up against peers.

Factors Shaping IHI's Quarterly Performance

The -15% quarterly slide built from mounting pressures on medical devices, including stretched valuations after 2025 gains and tighter macro conditions. Holdings like ISRG and EW lagged due to slower procedural growth and supply chain hurdles, while higher rates discounted future cash flows for innovation-focused firms. Earnings from peers like Stryker showed weaker demand in orthopedics and surgery, diverging from broader healthcare strength. Institutional outflows reached hundreds of millions over the year, with assets under management shrinking from $3.5B+ peaks, signaling fading confidence. Longer-term issues like hospital budget limits and rotation to cyclicals deepened the underperformance against health benchmarks. One thing that stands out is how these dynamics have persisted.

Why I Rely on Tickeron’s AI Screener for ETF Analysis

In my research, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs through filters on technical patterns, fundamentals, trends, volatility, and AI signals. It scans thousands of assets using criteria like industry, market cap, indicators, price patterns, and performance metrics, surfacing trade ideas, breakouts, and opportunities faster than manual methods. This has been invaluable for tracking sector performance and dynamic ETF moves like those in medical devices. I’m watching it closely for the next insights.

Looking Ahead for IHI: Key Factors to Monitor

Looking forward, keep an eye on demand signals in medical devices, such as hospital procedure volumes and Q2 earnings from leaders like SYK and ISRG. The macro backdrop—Federal Reserve rate decisions and inflation—will shape valuations for growth names. Major holdings' progress in areas like robotic surgery adoption matters too. Supply chain stability and regulatory shifts could also influence the ETF. Risks persist from extended weak demand or outflows, but improved flows or rate cuts might aid a rebound. This is important because it frames the potential path.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: IHI

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


IHI in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 08, 2026

IHI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where IHI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IHI's RSI Indicator exited the oversold zone, 27 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on IHI as a result. In 72 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

Following a +1.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHI advanced for three days, in 237 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 59 of 70 cases where IHI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for IHI turned negative on August 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 44 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

IHI moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IHI crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for IHI entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index, which measures the performance of the medical equipment sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC. The index includes medical equipment companies, including manufacturers and distributors of medical devices such as magnetic resonance imaging scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares U.S. Medical Devices ETF (IHI) ETF is 19.58B. The market cap for tickers in the group ranges from 384.52M to 175.27B. ABT holds the highest valuation in this group at 175.27B. The lowest valued company is OFIX at 384.52M.

High and low price notable news

The average weekly price growth across all stocks in the iShares U.S. Medical Devices ETF (IHI) ETF was 13%. For the same ETF, the average monthly price growth was 18%, and the average quarterly price growth was 216%. BFLY experienced the highest price growth at 19%, while PRCT experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the iShares U.S. Medical Devices ETF (IHI) ETF was -52%. For the same stocks of the ETF, the average monthly volume growth was -3% and the average quarterly volume growth was -14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 60
Price Growth Rating: 53
SMR Rating: 77
Profit Risk Rating: 91
Seasonality Score: -45 (-100 ... +100)
View a ticker or compare two or three
IHI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
415-670-2000
Web
www.ishares.com
Interact to see
Advertisement
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.
Shares of GSAT are surging approximately +15% intraday on March 25, 2026, following a prior session close of $61.09. The primary catalyst is a fresh analyst note from Scotiabank highlighting Globalstar's direct-to-device satellite connectivity bypassing cellular towers — most notably in Mexico — reinforcing the company's next-generation infrastructure thesis.
Shares of ADMA are declining approximately 12% in Wednesday's session, extending a steep two-day selloff. The primary catalyst is a short-seller research report published by Culper Research on March 24, 2026, alleging that ADMA engaged in channel stuffing to artificially inflate revenue growth.
Honeywell International (HON) and TransDigm Group (TDG) are prominent players in the aerospace and industrials sector, benefiting from rising air travel demand, defense spending, and aftermarket services. This stock comparison evaluates their business models, recent performance, and market positioning to help traders and investors assess relative strengths in the current environment. With global aviation recovery and geopolitical tensions supporting sector tailwinds, professionals seeking exposure to aerospace growth versus diversified industrials stability will find these insights relevant for portfolio decisions and relative performance analysis.
PL shares are surging approximately +15% in Wednesday's session, trading near $35.89, pushing back toward the stock's 52-week high of $36.28 set on March 20, 2026. Primary catalyst: Continued momentum from a blockbuster Q4 fiscal 2026 earnings report delivered March 19, which sent revenue 41% higher year-over-year to $86.8 million, well above the $78 million Wall Street consensus.
ASTS shares surged approximately +11.00% in active intraday trading on March 25, 2026, moving from a prior close of $86.98 to approximately $96.55. The primary driver is a broad space sector rally fueled by renewed SpaceX IPO speculation, lifting satellite and space-related equities across the board.
FUBO shares are set to open about 12% lower in Wednesday’s premarket session after closing the prior day at roughly $12.02. The decline follows a strong multi-week rally powered by balance-sheet news, including the repurchase of $140.2 million of 2026 convertible notes and improving profitability trends.
One & One Green Technologies Inc. (YDDL) shares are indicated down about 13% in Wednesday’s premarket session after closing the prior regular session at $12.00. The stock had just surged 15.6% in the latest completed session, jumping from a prior close of $10.38 to $12.00, leaving it vulnerable to swift profit‑taking and volatility.
AVXL shares are indicated down about 33% in Wednesday’s premarket session, after closing the prior regular session at $4.19. The slide follows a recent drop triggered by a wider‑than‑expected fourth‑quarter loss and ongoing questions about the company’s late‑stage neurology pipeline.
AUGO shares are trading roughly 9% higher in Wednesday action, moving from a prior close of $66.42 to around $72.40 intraday. The stock’s advance extends a powerful year-long rally underpinned by record 2025 production, surging Adjusted EBITDA, and a recently declared cash dividend of $0.66 per share.
NAVN shares are surging approximately +25% in premarket trading on March 26, 2026, following a blockbuster earnings report released after the close of the prior session. Primary catalyst: Q4 fiscal year 2026 results delivered a significant beat — revenue of $178 million rose 35% year-over-year, surpassing analyst forecasts by nearly 10%.
OLPX surged approximately +50.38% in premarket trading on March 26, 2026, from a previous close of $1.33 to approximately $2.00, with an intraday premarket high of $2.03. The primary catalyst is a definitive acquisition agreement by German consumer goods giant Henkel AG to purchase Olaplex for $2.06 per share in an all-cash deal, valuing the company at approximately $1.4 billion.
TASK shares are down approximately -36% in premarket trading on March 26, 2026, the stock's official ex-dividend date for its special $3.65 per share cash dividend. The $3.65 special cash dividend — exceeding 25% of the stock's pre-ex-div market value — triggered a mandatory Nasdaq-prescribed price adjustment on today's open.
MLKN shares are down approximately 18.90% in premarket trading on March 26, 2026, falling to $15.70 from the prior session's close of $19.36. The primary catalyst is a double miss on both earnings and revenue in the company's fiscal Q3 2026 report released after the close on March 25.
Wave Life Sciences (WVE) shares are tumbling approximately 51% in premarket trading on March 26, 2026, from a prior close of $12.30 to approximately $6.03. The primary catalyst is the release of highly anticipated INLIGHT Phase 1 clinical data for WVE-007, the company's investigational INHBE GalNAc-siRNA obesity treatment, with results falling materially short of investor expectations.
APP is trading approximately 6% lower in premarket trading on March 26, 2026, extending a multi-session losing streak. The prior regular-session close (March 25, 2026) stood at $435.91, itself already down 5.02% from the day before, making the premarket slide a continuation of accelerating selling pressure.
KOD shares surged approximately +50% in premarket trading on Thursday, March 26, 2026, from a prior closing price of $22.75 to approximately $34.13. The primary catalyst is a landmark readout: the GLOW2 Phase 3 trial of Zenkuda (tarcocimab tedromer) in diabetic retinopathy met its primary endpoint with overwhelming statistical significance.